Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01920932 · ClinicalTrials.gov registry record · Phase 2
Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma
A Phase 2 study of Stage II Childhood Hodgkin Lymphoma and Stage III Childhood Hodgkin Lymphoma, sponsored by St. Jude Children's Research Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
- 6
- Study locations
NCT01920932 is a Phase 2 study of Stage II Childhood Hodgkin Lymphoma and Stage III Childhood Hodgkin Lymphoma that is active but no longer recruiting, run by St. Jude Children's Research Hospital. The registered enrollment target is 77 participants. The trial reports 6 study locations across 5 states.
The verdict
NCT01920932, a Phase 2 study of Stage II Childhood Hodgkin Lymphoma and Stage III Childhood Hodgkin Lymphoma, is active but no longer recruiting, sponsored by St. Jude Children's Research Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
- 6
- Study locations
Study Summary
This pilot phase II trial studies how well giving brentuximab vedotin, combination chemotherapy, and radiation therapy works in treating younger patients with stage IIB, IIIB or IV Hodgkin lymphoma. Monoclonal antibodies, such as brentuximab vedotin, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer killing substances to them. Drugs used in chemotherapy, such as etoposide, prednisone, doxorubicin hydrochloride, cyclophosphamide, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. Giving brentuximab vedotin with combination chemotherapy may kill more cancer cells and reduce the need for radiation therapy.
Conditions Studied
Interventions
- DRUG prednisone
- DRUG cyclophosphamide
- DRUG doxorubicin
- DRUG brentuximab vedotin
- DRUG etoposide
Study Locations (6)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Dana-Farber Harvard Cancer Center - Boston
California
- Lucile Packard Children's Hospital Stanford University - Palo Alto
Illinois
- St. Jude Midwest Affiliate - Peoria
Maine
- Maine Children's Cancer Program (MCCP) - Scarborough
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2013-08-12 |
| Est. Completion | 2028-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01920932
The ClinicalTrials.gov registry entry for NCT01920932 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Stage II Childhood Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which prednisone is the first listed.
NCT01920932 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Massachusetts, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT01920932 about?
NCT01920932 is a clinical study titled "Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma". This pilot phase II trial studies how well giving brentuximab vedotin, combination chemotherapy, and radiation therapy works in treating younger patients with stage IIB, IIIB or IV Hodgkin lymphoma. Monoclonal antibodies, such as brentuximab vedotin, can block cancer growth in different ways. Some b...
What is the current status of trial NCT01920932?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2013-08-12. Estimated completion is 2028-05.
What conditions does trial NCT01920932 study?
This clinical trial studies the following conditions: Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma.
What interventions are being tested in trial NCT01920932?
The interventions under investigation include: prednisone (DRUG), cyclophosphamide (DRUG), doxorubicin (DRUG), brentuximab vedotin (DRUG), etoposide (DRUG).
Who is sponsoring clinical trial NCT01920932?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01920932 being conducted?
This trial has 6 study locations across California, Illinois, Maine, Massachusetts, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Stage II Childhood Hodgkin Lymphoma
All registered trials for this condition
Stage III Childhood Hodgkin Lymphoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.